PPARG and type 2 diabetes mellitus: Studies show that the drug class thiazolidinediones, used in type 2 diabetes treatment, inhibit dopaminergic neuron loss by peroxisome proliferator-activated receptor gamma (PPAR-γ) activation and act in a neuroprotective manner in PD animal models.